• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

MIGS and cataract surgery option offers positive results

Digital EditionOphthalmology Times: May 2021
Volume 46
Issue 8

Retrospective review highlights the sustained efficacy of combination procedure.

Reviewed by Karsten Klabe, MD

Results from 5 years of follow-up show that minimally invasive glaucoma surgery (MIGS) with simultaneous implantation of 2 trabecular microbypass stents (iStent Inject, Glaukos) combined with phacoemulsification is safe and provides durable moderate lowering of IOP.

It also reduced the burden of topical ocular hypotensive medications, according to Karsten Klabe, MD.

“A number of MIGS procedures are now available, and [although] they have shown encouraging initial results in premarketing clinical trials, data are needed to understand their long-term efficacy and safety,” said Klabe, who is in private practice at Breyer Kaymak and Klabe Augenchirurgie in Düsseldorf, Germany, and is a partner at International Vision Correction Research Center of the Universitäts Heidelberg-Augenklinik.

Related: Standalone MIGS delivers durable IOP control in phakic eyes

“Our experience using combined iStent Inject implantation and cataract surgery shows that with selection of appropriate candidates, only rare patients will need further intervention for their glaucoma, and the majority can become medication-free,” he said. “Considering the latter benefit, adding the iStent Inject when patients need cataract surgery addresses the adherence issues we face when prescribing glaucoma therapies and their potential to cause ocular surface disease so that patients have a higher quality of life.”

FIGURE 1. The 2 microstents are injected into the eye using a specially designed applicator. (Image courtesy of Karsten Klabe, MD)

FIGURE 1. The 2 microstents are injected into the eye using a specially designed applicator. (Image courtesy of Karsten Klabe, MD)

Klabe’s study of outcomes after combined cataract surgery with implantation of the iStent Inject was a retrospective review that included 164 eyes of 103 patients.

The cohort had a mean age of 75.4 years and the majority were male.

Primary open-angle glaucoma was the predominant diagnosis (82%), and the remaining eyes had pseudoexfoliation glaucoma (18%).

Preoperatively, the 164 eyes had a mean IOP with medication of 18.5 mm Hg. The average mean deviation on the visual field was -6.19 dB MD, and mean cup/disc ratio was 0.59.

Related: Study examines pairing phacoemulsification, implantation of microbypass stents

Twenty-nine eyes (18%) had previously been treated with selective laser trabeculoplasty (SLT), and 8 eyes had undergone previous surgery that included placement of the Xen Gel Stent (Allergan), canaloplasty, trabeculectomy, or iridotomy.

All of the previous interventions were performed more than 3 months prior to the combination cataract/MIGS procedure.

Of the 164 implanted eyes, 157 had 24 months of follow-up; 129, 85, and 61 eyes were seen at months 26, 48, and 60 months, respectively.

Mean IOP decreased to 16.0 mm Hg at 1 month after surgery, 15.5 mm Hg at month 6, and stabilized at that level (±0.5 mm Hg) for the remaining follow-up duration.

At baseline, patients were taking a mean of 1.47 medications to lower IOP (range 0-4). Throughout follow-up, no patients were taking more than 2 medications, and the mean of medications used daily ranged from 0.17 to 0.23 without any evidence of an increase over time.

Related: Drainage device offers IOP lowering capabilities at 1 year

Safety highlights

Highlighting the safety of the combination procedure, Klabe reported that there were very few complications in the series. The majority of the complications were minor and related to the MIGS procedure.

They included hyphema in 11 eyes (6.7%), persistent hypotony (IOP < 10 mm Hg for more than 1 month) in 2 eyes (1.2%), and iris incarceration in 2 eyes (1.2%). In addition, there were 7 cases (4.3%) of stent occlusion.

“The cases of occlusion were observed later than 3 months after surgery and were related to implantation that was too deep,” Klabe said. “It is very important to hold the injector in place without pushing it forward during implantation. However, the introduction of the iStent [inject] with a wider flange solved the risk of overimplantation.”

Data regarding the need for further glaucoma surgery provided further evidence of the efficacy of the combination surgery.

Related: Eliminating the potential land mines in glaucoma surgery

Over the 5 years of follow-up, only 7 eyes (4.3%) underwent a second procedure, which included placement of the Xen Gel Stent in 3 eyes, implantation of the Preserflo MicroShunt (Santen) in 2 eyes, SLT in 1 eye, and cyclophotocoagulation in 1 eye.

Surgical technique
The 2 microstents are preloaded in a specially designed applicator in a procedure that has a short learning curve but requires minimal additional settings and instruments, according to Klabe.

“When combined with phacoemulsification, the glaucoma portion of the procedure can be done either prior to or after the cataract surgery, according to the surgeon’s preference,” he said.

Related: Surgical decision-making in the era of MIGS

Klabe explained that he prefers to perform the stent implantation at the end of the surgery, noting that the deep anterior chamber offers excellent visibility and lowers the risk of iris damage.

“On the other hand, the main incision in my cases is only 2.2 mm and prevents the loss of [the] ophthalmic viscosurgical device and flattening of the anterior chamber,” he said. “Use of a Vold Gonioprism with retention ring may be helpful because of the low pressure on the cornea that guarantees good visibility.”


Karsten Klabe, MD
Klabe is a consultant/adviser to, study investigator for, and recipient of travel stipends from Glaukos and other companies that market devices for MIGS.

Related Videos
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
Deb Ristvedt, DO's CIME 2024 Talk Highlights Innovations in Treating Glaucoma via the Trabecular Meshwork
Dr. Inder Paul Singh's Insights: Improving Glaucoma Outcomes with Early Intervention and Reduced Medication
CIME 2024: Neda Shamie, MD, reports on a morning session packed with refractive surgery options, retina, glaucoma, and a 'mite-y' Demodex discussion
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
© 2024 MJH Life Sciences

All rights reserved.